Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | DNM2 | P50570 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913709 | 1.00 | CA1 (0.49) | CA1CA2CA9SLC29A1KCNH3 | |
| SCHEMBL14725030 | 0.92 | TLR8 (0.51) | CA1CA2CA9SLC29A1KMT2A | |
| SCHEMBL12373453 | 0.89 | TLR8 (0.51) | CA1CA2CA9SLC29A1KCNH3 | |
| SCHEMBL2784426 | 0.89 | SLC29A1 (0.57) | CA1CA2CA9SLC29A1KCNH3 | |
| SCHEMBL20375134 | 0.86 | CYP1A2 (0.52) | CA1CA2CA9KCNH3KMT2A | |
| SCHEMBL428279 | 0.86 | CYP1A2 (0.52) | CA1CA2CA9KCNH3KMT2A | |
| SCHEMBL21587503 | 0.86 | SLC29A1 (0.55) | CA1CA2CA9SLC29A1KCNH3 | |
| SCHEMBL15402297 | 0.85 | KMT2A (0.51) | CA1CA2CA9SLC29A1KCNH3 | |
| SCHEMBL21527302 | 0.84 | CA12 (0.49) | CA1CA2CA9KCNH3KMT2A | |
| SCHEMBL17564594 | 0.84 | KMT2A (0.71) | CA1CA2CA9KCNH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | Mori, Kunio (JP) | 2017-11-23 | — | — | US | disclosed |
| US-9790242-B2 | Surface treatment method, surface treatment agent, and novel compound | Mori, Kunio (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | EPCAM, ITGAM, MET | CA1 486/4885CA2 1279/4885CA9 2898/4885 |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | EPCAM, MET, ITGAM | CA1 159/4885CA2 860/4885CA9 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.